Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Cyclooxygenase-2 Inhibition and Gastric Cancer

Author(s): Xiao Hua Jiang and C. Y. Wong

Volume 9, Issue 27, 2003

Page: [2281 - 2288] Pages: 8

DOI: 10.2174/1381612033453983

Price: $65

Abstract

Epidemiological evidences suggest that chronic use of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) might be associated with a reduced risk of gastrointestinal cancers, including gastric cancer. The pre-cancerous gastric lesions and gastric cancers over-expressed cyclooxygenase (COX)-2. This overexpression not only is associated with Helicobacter pylori infection, but also maybe due to exposure to carcinogens. Targeted inhibition of COX, especially the COX-2 isoform, can lead to growth inhibition and apoptosis of gastric cancer in vitro. Various mechanisms, including COX-dependent and COX-independent pathways, have been identified and will be discussed in this article. Animal xenograft models have confirmed the tumor suppressing effects of COX-2 inhibitors. Human studies are underway to examine the use of COX-2 inhibitor in the treatment of pre-cancerous lesions. COX-2 inhibitors have a promising role in the prevention and treatment of gastric cancer.

Keywords: gastric cancer, apoptosis, prostaglandin, cyclooxygenase, prevention, epidemiology, premalignant lesions, intervention


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy